标题
Emerging targeted drug delivery strategies toward ovarian cancer
作者
关键词
Targeted delivery, Ovarian cancer, Drug conjugates, Nanomedicine, Drug resistance, Combination therapy
出版物
ADVANCED DRUG DELIVERY REVIEWS
Volume 178, Issue -, Pages 113969
出版商
Elsevier BV
发表日期
2021-09-09
DOI
10.1016/j.addr.2021.113969
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- α3 integrin-binding peptide-functionalized polymersomes loaded with volasertib for dually-targeted molecular therapy for ovarian cancer
- (2021) Zhe Wang et al. Acta Biomaterialia
- Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I
- (2021) K.N. Moore et al. ANNALS OF ONCOLOGY
- Barriers to antibody therapy in solid tumors, and their solutions
- (2021) Yasuhiro Matsumura CANCER SCIENCE
- Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer
- (2020) David M. O'Malley et al. GYNECOLOGIC ONCOLOGY
- Preclinical Activity of Sacituzumab Govitecan, an Antibody-Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2 (Trop-2) Linked to the Active Metabolite of Irinotecan (SN-38), in Ovarian Cancer
- (2020) Emanuele Perrone et al. Frontiers in Oncology
- Tumor extravasation and infiltration as barriers of nanomedicine for high efficacy: The current status and transcytosis strategy
- (2020) Quan Zhou et al. BIOMATERIALS
- Targeting Strategies for Tissue-Specific Drug Delivery
- (2020) Zongmin Zhao et al. CELL
- First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody–Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors
- (2020) Raffit Hassan et al. JOURNAL OF CLINICAL ONCOLOGY
- Photoactivatable Prodrug-Backboned Polymeric Nanoparticles for Efficient Light-Controlled Gene Delivery and Synergistic Treatment of Platinum-Resistant Ovarian Cancer
- (2020) Qingfei Zhang et al. NANO LETTERS
- Tumor-Targeting Polycaprolactone Nanoparticles with Codelivery of Paclitaxel and IR780 for Combinational Therapy of Drug-Resistant Ovarian Cancer
- (2020) Qianqian Pan et al. ACS Biomaterials-Science & Engineering
- Actively targeted nanomedicines for precision cancer therapy: Concept, construction, challenges and clinical translation
- (2020) Wenxing Gu et al. JOURNAL OF CONTROLLED RELEASE
- CA125 and Ovarian Cancer: A Comprehensive Review
- (2020) Parsa Charkhchi et al. Cancers
- Is Targeting the Folate Receptor in Ovarian Cancer Coming of Age?
- (2019) Michael J. Birrer et al. ONCOLOGIST
- Acquired Resistance to Antibody-Drug Conjugates
- (2019) Denis Collins et al. Cancers
- Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1–2 trial
- (2019) Johann S de Bono et al. LANCET ONCOLOGY
- Epithelial ovarian cancer
- (2019) Stephanie Lheureux et al. LANCET
- First-in-human, phase I study of PF-06647263, an anti-EFNA4 calicheamicin antibody-drug conjugate, in patients with advanced solid tumors
- (2019) Ignacio Garrido-Laguna et al. INTERNATIONAL JOURNAL OF CANCER
- Phase 1 dose escalation study of XMT-1536, a novel NaPi2b-targeting antibody-drug conjugate (ADC), in patients (pts) with solid tumors likely to express NaPi2b.
- (2019) Anthony W. Tolcher et al. JOURNAL OF CLINICAL ONCOLOGY
- Anti-tumor efficacy of folate modified PLGA-based nanoparticles for the co-delivery of drugs in ovarian cancer
- (2019) Shu Li et al. Drug Design Development and Therapy
- Ligand density on nanoparticles: A parameter with critical impact on nanomedicine
- (2019) Alaaldin M. Alkilany et al. ADVANCED DRUG DELIVERY REVIEWS
- HER2-Specific Reduction-Sensitive Immunopolymersomes with High Loading of Epirubicin for Targeted Treatment of Ovarian Tumor
- (2019) Lin Ding et al. BIOMACROMOLECULES
- Dually Active Targeting Nanomedicines Based on a Direct Conjugate of Two Purely Natural Ligands for Potent Chemotherapy of Ovarian Tumors
- (2019) Yu Yan et al. ACS Applied Materials & Interfaces
- Probody Therapeutics: An Emerging Class of Therapies Designed to Enhance On-Target Effects with Reduced Off-Tumor Toxicity for Use in Immuno-Oncology
- (2019) Karen A. Autio et al. CLINICAL CANCER RESEARCH
- Doxorubicin combined with betulinic acid or lonidamine in RGD ligand-targeted pH-sensitive micellar system for ovarian cancer treatment
- (2019) Xin Jin et al. INTERNATIONAL JOURNAL OF PHARMACEUTICS
- In vitro evaluation of folate-modified PLGA nanoparticles containing paclitaxel for ovarian cancer therapy
- (2019) Marcela Tavares Luiz et al. Materials Science & Engineering C-Materials for Biological Applications
- Paclitaxel-Loaded Self-Assembled Lipid Nanoparticles as Targeted Drug Delivery Systems for the Treatment of Aggressive Ovarian Cancer
- (2018) Jiali Zhai et al. ACS Applied Materials & Interfaces
- Corrigendum to ‘Tumor-targeting peptides from combinatorial libraries’ [Adv Drug Deliv Rev.110–111 (2017) 13–37]
- (2018) Ruiwu Liu et al. ADVANCED DRUG DELIVERY REVIEWS
- Anti-NaPi2b antibody–drug conjugate lifastuzumab vedotin (DNIB0600A) compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II study
- (2018) S Banerjee et al. ANNALS OF ONCOLOGY
- Ovarian cancer statistics, 2018
- (2018) Lindsey A. Torre et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Hypocrellin B-loaded, folate-conjugated polymeric micelle for intraperitoneal targeting of ovarian cancer in vitro and in vivo
- (2018) Jie Li et al. CANCER SCIENCE
- Follicle-stimulating hormone peptide-conjugated nanoparticles for targeted shRNA delivery lead to effective gro-α silencing and antitumor activity against ovarian cancer
- (2018) Shan-Shan Hong et al. DRUG DELIVERY
- Transferrin and octaarginine modified dual-functional liposomes with improved cancer cell targeting and enhanced intracellular delivery for the treatment of ovarian cancer
- (2018) Pranali Deshpande et al. DRUG DELIVERY
- Selective delivery of PLXDC1 small interfering RNA to endothelial cells for anti-angiogenesis tumor therapy using CD44-targeted chitosan nanoparticles for epithelial ovarian cancer
- (2018) Ga Hee Kim et al. DRUG DELIVERY
- FORWARD I: a Phase III study of mirvetuximab soravtansine versus chemotherapy in platinum-resistant ovarian cancer
- (2018) Kathleen N Moore et al. Future Oncology
- Hyaluronic acid-based biopharmaceutical delivery and tumor-targeted drug delivery system
- (2018) Gangliang Huang et al. JOURNAL OF CONTROLLED RELEASE
- GE11-Directed Functional Polymersomal Doxorubicin as an Advanced Alternative to Clinical Liposomal Formulation for Ovarian Cancer Treatment
- (2018) Yan Zou et al. MOLECULAR PHARMACEUTICS
- Dual-targeted nanomedicines for enhanced tumor treatment
- (2018) Yaqin Zhu et al. Nano Today
- Hyaluronic acid conjugated nanoparticle delivery of siRNA against TWIST reduces tumor burden and enhances sensitivity to cisplatin in ovarian cancer
- (2018) Sophia A. Shahin et al. Nanomedicine-Nanotechnology Biology and Medicine
- Plectin-targeted liposomes enhance the therapeutic efficacy of a PARP inhibitor in the treatment of ovarian cancer
- (2018) Siva Sai Krishna Dasa et al. Theranostics
- Overcoming Ovarian Cancer Drug Resistance with a Cold Responsive Nanomaterial
- (2018) Hai Wang et al. ACS Central Science
- A Single-Agent Dual-Specificity Targeting of FOLR1 and DR5 as an Effective Strategy for Ovarian Cancer
- (2018) Gururaj Shivange et al. CANCER CELL
- Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer
- (2018) Kathleen N. Moore et al. GYNECOLOGIC ONCOLOGY
- Anetumab ravtansine inhibits tumor growth and shows additive effect in combination with targeted agents and chemotherapy in mesothelin-expressing human ovarian cancer models
- (2018) Maria Quanz et al. Oncotarget
- Multivalent Ligand Binding to Cell Membrane Antigens: Defining the Interplay of Affinity, Valency, and Expression Density
- (2018) Clifford M. Csizmar et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
- (2018) Kathleen Moore et al. NEW ENGLAND JOURNAL OF MEDICINE
- Characterization of folate receptor alpha (FRα) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: A phase I expansion study of the FRα-targeting antibody-drug conjugate mirvetuximab soravtansine
- (2017) Lainie P. Martin et al. GYNECOLOGIC ONCOLOGY
- Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha–Targeting Antibody–Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study
- (2017) Kathleen N. Moore et al. JOURNAL OF CLINICAL ONCOLOGY
- Folate-mediated chemotherapy and diagnostics: An updated review and outlook
- (2017) Leyuan Xu et al. JOURNAL OF CONTROLLED RELEASE
- RNA nanoparticles harboring annexin A2 aptamer can target ovarian cancer for tumor-specific doxorubicin delivery
- (2017) Fengmei Pi et al. Nanomedicine-Nanotechnology Biology and Medicine
- A PTK7-targeted antibody-drug conjugate reduces tumor-initiating cells and induces sustained tumor regressions
- (2017) Marc Damelin et al. Science Translational Medicine
- A water-soluble nucleolin aptamer-paclitaxel conjugate for tumor-specific targeting in ovarian cancer
- (2017) Fangfei Li et al. Nature Communications
- Engineered fusion protein-loaded gold nanocarriers for targeted co-delivery of doxorubicin and erbB2-siRNA in human epidermal growth factor receptor-2+ ovarian cancer
- (2017) Rajesh Kotcherlakota et al. Journal of Materials Chemistry B
- PRECEDENT: A randomized phase II trial comparing EC145 and pegylated liposomal doxorubicin (PLD) in combination, versus PLD alone, in subjects with platinum-resistant ovarian cancer.
- (2017) R. W. Naumann et al. JOURNAL OF CLINICAL ONCOLOGY
- Integrin-Targeting Knottin Peptide-Drug Conjugates Are Potent Inhibitors of Tumor Cell Proliferation
- (2016) Nick Cox et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody–drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer
- (2016) J. F. Liu et al. ANNALS OF ONCOLOGY
- Integrated self-assembling drug delivery system possessing dual responsive and active targeting for orthotopic ovarian cancer theranostics
- (2016) Chun-Jui Lin et al. BIOMATERIALS
- Folic acid tagged nanoceria as a novel therapeutic agent in ovarian cancer
- (2016) Miriana Hijaz et al. BMC CANCER
- Follicle-Stimulating Hormone Receptor Is Expressed by Most Ovarian Cancer Subtypes and Is a Safe and Effective Immunotherapeutic Target
- (2016) Alfredo Perales-Puchalt et al. CLINICAL CANCER RESEARCH
- Precision targeted therapy of ovarian cancer
- (2016) Justin Sapiezynski et al. JOURNAL OF CONTROLLED RELEASE
- Carboplatin-Complexed and cRGD-Conjugated Unimolecular Nanoparticles for Targeted Ovarian Cancer Therapy
- (2016) Yuyuan Wang et al. MACROMOLECULAR BIOSCIENCE
- Phase I Study of DMOT4039A, an Antibody-Drug Conjugate Targeting Mesothelin, in Patients with Unresectable Pancreatic or Platinum-Resistant Ovarian Cancer
- (2016) C. D. Weekes et al. MOLECULAR CANCER THERAPEUTICS
- Development of a Novel Antibody–Drug Conjugate for the Potential Treatment of Ovarian, Lung, and Renal Cell Carcinoma Expressing TIM-1
- (2016) Lawrence J. Thomas et al. MOLECULAR CANCER THERAPEUTICS
- Cyclic RGDfK Peptide Functionalized Polymeric Nanocarriers for Targeting Gemcitabine to Ovarian Cancer Cells
- (2016) Hitesh Kulhari et al. MOLECULAR PHARMACEUTICS
- Discovery and characterization of a high-affinity and high-specificity peptide ligand LXY30 for in vivo targeting of α3 integrin-expressing human tumors
- (2016) Wenwu Xiao et al. EJNMMI Research
- Ovarian cancer
- (2016) Ursula A. Matulonis et al. Nature Reviews Disease Primers
- Folate Receptor Targeted Delivery of siRNA and Paclitaxel to Ovarian Cancer Cells via Folate Conjugated Triblock Copolymer to Overcome TLR4 Driven Chemotherapy Resistance
- (2015) Steven K. Jones et al. BIOMACROMOLECULES
- Understanding the Unique Attributes of MUC16 (CA125): Potential Implications in Targeted Therapy
- (2015) S. Das et al. CANCER RESEARCH
- Preclinical Development of an Anti-NaPi2b (SLC34A2) Antibody-Drug Conjugate as a Therapeutic for Non-Small Cell Lung and Ovarian Cancers
- (2015) K. Lin et al. CLINICAL CANCER RESEARCH
- Anti-EFNA4 Calicheamicin Conjugates Effectively Target Triple-Negative Breast and Ovarian Tumor-Initiating Cells to Result in Sustained Tumor Regressions
- (2015) M. Damelin et al. CLINICAL CANCER RESEARCH
- Ovarian cancer targeted hyaluronic acid-based nanoparticle system for paclitaxel delivery to overcome drug resistance
- (2015) Liping Wang et al. DRUG DELIVERY
- Long-Term Survival Advantage and Prognostic Factors Associated With Intraperitoneal Chemotherapy Treatment in Advanced Ovarian Cancer: A Gynecologic Oncology Group Study
- (2015) Devansu Tewari et al. JOURNAL OF CLINICAL ONCOLOGY
- Nanomedicine in cancer therapy: Challenges, opportunities, and clinical applications
- (2015) Andreas Wicki et al. JOURNAL OF CONTROLLED RELEASE
- IMGN853, a Folate Receptor- (FR )-Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FR -Expressing Tumors
- (2015) O. Ab et al. MOLECULAR CANCER THERAPEUTICS
- Ovarian cancer: beyond resistance
- (2015) David Holmes NATURE
- Whole–genome characterization of chemoresistant ovarian cancer
- (2015) Ann-Marie Patch et al. NATURE
- Up-regulation of CD44 in the development of metastasis, recurrence and drug resistance of ovarian cancer
- (2015) Yan Gao et al. Oncotarget
- Follicle-Stimulating Hormone Receptor as a Target in the Redirected T-cell Therapy for Cancer
- (2015) K. Urbanska et al. Cancer Immunology Research
- Formulation development of a novel targeted theranostic nanoemulsion of docetaxel to overcome multidrug resistance in ovarian cancer
- (2014) Srinivas Ganta et al. DRUG DELIVERY
- Imaging the Folate Receptor on Cancer Cells with 99mTc-Etarfolatide: Properties, Clinical Use, and Future Potential of Folate Receptor Imaging
- (2014) A. H. Maurer et al. JOURNAL OF NUCLEAR MEDICINE
- Ovarian cancer
- (2014) Gordon C Jayson et al. LANCET
- Anetumab Ravtansine: A Novel Mesothelin-Targeting Antibody-Drug Conjugate Cures Tumors with Heterogeneous Target Expression Favored by Bystander Effect
- (2014) S. Golfier et al. MOLECULAR CANCER THERAPEUTICS
- An Antimesothelin-Monomethyl Auristatin E Conjugate with Potent Antitumor Activity in Ovarian, Pancreatic, and Mesothelioma Models
- (2014) S. J. Scales et al. MOLECULAR CANCER THERAPEUTICS
- Abstract 4628: Anti-tumor activity and pharmacokinetics of the anti-FOLR1-maytansinoid conjugate IMGN853 is maintained over a wide range of maytansinoid-to-antibody ratios
- (2012) Kathleen R. Whiteman et al. CANCER RESEARCH
- "OA02" Peptide Facilitates the Precise Targeting of Paclitaxel-Loaded Micellar Nanoparticles to Ovarian Cancer In Vivo
- (2012) K. Xiao et al. CANCER RESEARCH
- Canine malignant melanoma alpha-3 integrin binding peptides
- (2011) Olulanu H. Aina et al. VETERINARY IMMUNOLOGY AND IMMUNOPATHOLOGY
- The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect
- (2010) Jun Fang et al. ADVANCED DRUG DELIVERY REVIEWS
- Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
- (2010) M William Audeh et al. LANCET
- Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer
- (2010) Ignace Vergote et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase II trial of cetuximab and carboplatin in relapsed platinum-sensitive ovarian cancer and evaluation of epidermal growth factor receptor expression: A Gynecologic Oncology Group study
- (2008) Angeles Alvarez Secord et al. GYNECOLOGIC ONCOLOGY
- Antitumoral activity of PEG–gemcitabine prodrugs targeted by folic acid
- (2008) Gianfranco Pasut et al. JOURNAL OF CONTROLLED RELEASE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started